Bimatoprost
Prostaglandin Analogues
Sold as Durysta · Ganfort · Lumigan · VIZIBIM · LATISSE
- Drug class
- Prostaglandin Analogues
- Availability
- Prescription only
- Routes
- Ophthalmic, Topical
- Markets covered
- 4
- Products on record
- 126
- FDA reports (12 mo)
- 802
Overview
Bimatoprost is an active pharmaceutical ingredient in the Prostaglandin Analogues group (S01EE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 109 | May 29, 2026 |
| CA Canada | Health Canada | 12 | April 23, 2026 |
| US United States | FDA | 3 | January 9, 2026 |
| EU European Union | EMA | 2 | November 18, 2024 |
GBUnited Kingdom· MHRA
109 products
Uses
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).
How to take
CACanada· Health Canada
12 products
Uses
1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.
Use as for adult patients.
How to take
USUnited States· FDA
3 products
Uses
03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. 03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
( 1 )
How to take
EUEuropean Union· EMA
2 products
Uses
Reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
How to take
Drug interactions
Known interactions involving Bimatoprost. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL068310357 · revised October 4, 2024
- [2]Health Canada (DPD) · 02324997 · revised March 22, 2025
- [3]FDA DailyMed · 059a60ec-aee2-4c… · revised July 17, 2023 [PDF]
- [4]European Medicines Agency · EMEA/H/C/000668 · revised November 18, 2024
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.